Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
about
Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapyThe complex molecular biology of amyotrophic lateral sclerosis (ALS)Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosisNeurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patientsVascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patientsParadoxical response of VEGF expression to hypoxia in CSF of patients with ALS.Potential drugs and methods for preventing or delaying the progression of Huntington's disease.Roles for VEGF in the adult.Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons.Modulation of vascular endothelial growth factor (VEGF) expression in motor neurons and its electrophysiological effects.Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis.Protein biomarkers for amyotrophic lateral sclerosis.ALS and oxidative stress: the neurovascular scenarioBiomarkers in amyotrophic lateral sclerosis: facts and future horizons.The neurobiology of amyotrophic lateral sclerosis.Hypoxia inducible factor-1 as a target for neurodegenerative diseases.CSF markers in amyotrophic lateral sclerosis.TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.EFNS guidelines on disease-specific CSF investigations.Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice.New treatments for denervating diseases.Vascular endothelial growth factor and amyotrophic lateral sclerosis: the interplay with exercise and noninvasive ventilation.Engineered 3D vascular and neuronal networks in a microfluidic platform.VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS).Autocrine production of IGF-I increases stem cell-mediated neuroprotection.Evolution of the VEGF-Regulated Vascular Network from a Neural Guidance SystemModifying effect of arterial hypertension on amyotrophic lateral sclerosisPhosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALSAssociation of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosisIntramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats
P2860
Q26999881-3E2F974E-5E24-43E6-AB54-047DBF97B365Q28263899-12378020-66C2-4E51-ABDB-93AF1C840F46Q33616384-26800A33-C58A-46CB-BDFC-1FD9DEBB6ED4Q33750190-C01EAF61-9487-41BD-86BB-C7B3C59C5B6DQ33985590-ECBDEECE-0F5C-4710-B70F-B8F56BCED96DQ34276055-A28AC7AA-7256-46E6-8DA2-A45539CCC141Q34549555-601B1F56-C4C4-4594-ACB2-50EDEBD233B6Q35052750-9606EFB7-B373-4A5F-B271-35954CB873DBQ35225943-9F25AAC6-544C-4DF3-AEBC-0E5C9A2216ECQ36142587-EE9B19CC-9FB9-4D5C-8DF8-04F787D355D9Q36142706-7E994C56-4E8D-4EC9-83DF-8D5D76AA6BE8Q36248647-C501A210-9C6F-4DC6-BB06-6D28C3DE3F2AQ36389531-3CCD9AF8-D035-4EE2-B417-4395E076B165Q36710448-46B92E0D-B52D-466D-A5A2-62DA4C9FAAFFQ36953434-5DD82F6A-2DF2-41E6-8441-71CD6F183C34Q37157841-76A223FD-B75E-41E5-B113-968C03B9364BQ37400451-C2B72EE1-10DA-4669-8175-A7CC83FA48D4Q37523903-50E73204-4629-44C7-A8EC-4B1B88D420DAQ37763285-617B778F-ED85-4288-963A-557783A91BA5Q37921345-49228496-F6EB-4B4B-AB79-78E223354047Q38007362-4EC41FDF-A901-434F-A39F-31C6F299C90BQ38326803-540B3FF9-F9E0-4947-AFF2-04629F5E5ECEQ39976271-D8544134-0CD3-4D1F-96BB-D0E4E3E71975Q45887127-D19CC2DB-F34D-4A7C-BB9D-7E043AA94575Q46439343-9D320682-4E30-4C97-9C34-AFE654FD80F6Q47980116-110E15FA-836D-4685-9C61-9DB493462469Q52629510-8CDD95CD-5009-4236-AE95-68F818A5BD9BQ53625185-37D73B80-A2AB-427C-BB51-DB79E9AB6714Q53655642-E3773FF9-A1A9-4B2E-A195-1299E8C49058Q56487095-E0BF46DB-4E16-4A34-8513-54ABE6637FB4Q57605693-C474B0DB-37DE-4A4C-AF17-B02F6CD730E5Q57774921-CE8DC4A7-0317-41EE-B11A-24EABE3A2D9BQ58125423-2BDEFBAA-72FF-4439-9EB2-7D8B81B3D2FAQ58278823-C9118A7C-B8B2-4E9B-BB8D-E9247F3A3EB6
P2860
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@en
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@nl
type
label
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@en
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@nl
prefLabel
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@en
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
@nl
P2093
P921
P1433
P1476
Low levels of the vascular endothelial growth factor in CSF from early ALS patients
@en
P2093
A B Tonnel
V Brunaud-Danel
P304
P356
10.1212/01.WNL.0000129913.44351.A3
P407
P577
2004-06-01T00:00:00Z